Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05091424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05091424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Recruiting
Start date
March 7, 2022
Completion date
February 10, 2032
Enrollment
332 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia or small lymphocytic lymphoma